The Relationship Between Symptom Prevalence and Severity and Cancer Primary Site in 796 Patients With Advanced Cancer

Abstract

Knowledge of differences in symptom experience between cancer sites may help better understand symptom pathophysiology. A total of 38 symptoms in 796 consecutive patients with advanced cancer were retrospectively analyzed. Symptom prevalence and severity were compared among the 12 primary site groups (PSGs) by the chi-square test. Pairwise comparisons determined which sites differed. Pain, fatigue, weakness, lack of energy, and anorexia had the highest overall prevalence but did not differ among PSGs. The 3 most common neuropsychological symptoms (insomnia, depression, and anxiety) also did not vary among PSGs. Nineteen (50%) symptoms varied significantly between PSGs, in prevalence (17), severity (14), or both (12). Nine of 17, 6 of 14, and 6 of 12 were gastrointestinal symptoms. Symptoms which varied by PSGs can be included in cancer site-specific symptom assessment instruments.

Keywords

cancer symptom prevalence severity primary site symptom assessment

Get full access to this article

View all access options for this article.

References

Komurcu S. , Nelson KA , Walsh D. , Donnelly SM , Homsi J. , Abdullah O. Common symptoms in advanced cancer. Semin Oncol. 2000;27(1):24-33.

Cleeland CS Cancer-related symptoms. Semin Radiat Oncol. 2000;10(3):175-190.

Donnelly S. , Walsh D. The symptoms of advanced cancer. Semin Oncol. 1995;22(2suppl3):67-72.

Kirkova J. , Walsh D. , Rybicki L. , et al. Symptom severity and distress in advanced cancer. Palliat Med. 2010;24(3):330-339.

Portenoy RK , Thaler HT , Kornblith AB , et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res. 1994;3(3):183-189.

Grond S. , Zech D. , Diefenbach C. , Bischoff A. Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage. 1994;9(6):372-382.

Grosvenor M. , Bulcavage L. , Chlebowski RT Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. Cancer. 1989 ;63(2):330-334.

Ahles TA , Ruckdeschel JC , Blanchard EB Cancer-related pain-I. Prevalence in an outpatient setting as a function of stage of disease and type of cancer. J Psychosom Res. 1984;28(2):115-119.

Vainio A. , Auvinen A. Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom prevalence group. J Pain Symptom Manage. 1996;12(1): 3-10.

10.

Hickok JT , Morrow GR , Roscoe JA , Mustian K. , Okunieff P. Occurrence, severity, and longitudinal course of twelve common symptoms in 1129 consecutive patients during radiotherapy for cancer. J Pain Symptom Manage. 2005;30(5):433-442.

11.

Daut RL , Cleeland CS The prevalence and severity of pain in cancer. Cancer. 1982;50(9):1913-1918.

12.

Rustoen T. , Fossa SD , Skarstein J. , Moum T. The impact of demographic and disease-specific variables on pain in cancer patients. J Pain Symptom Manage. 2003;26(2):696-704.

13.

Stone P. , Richards M. , A’Hern R. , Hardy J. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol. 2000;11(5):561-567.

14.

Wang XS , Wang Y. , Guo H. , Mendoza TR , Hao XS , Cleeland CS Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients. Cancer. 2004;101(8):1890-1901.

15.

Chiu TY , Hu WY , Chen CY Prevalence and severity of symptoms in terminal cancer patients: a study in Taiwan. Support Care Cancer. 2000;8(4):311-313.

16.

Donnelly S. , Walsh D. , Rybicki L. The symptoms of advanced cancer: identification of clinical and research priorities by assessment of prevalence and severity. J Palliat Care. 1995; 11(1):27-32.

17.

Walsh D. , Donnelly S. , Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer. 2000;8(3):175-179.

18.

Walsh D. , Rybicki L. , Nelson KA , Donnelly S. Symptoms and prognosis in advanced cancer. Support Care Cancer . 2002; 10(5):385-388.

19.

Chang VT , Hwang SS , Feuerman M. , Kasimis BS , Thaler HT The memorial symptom assessment scale short form (MSAS-SF). Cancer. 2000;89(5):1162-1171.

20.

Davis MP , Walsh D. , Lagman R. , Yavuzsen T. Early satiety in cancer patients: a common and important but underrecognized symptom. Support Care Cancer. 2006;14(7):693-698.

21.

Dudgeon DJ , Kristjanson L. , Sloan JA , Lertzman M. , Clement K. Dyspnea in cancer patients: prevalence and associated factors. J Pain Symptom Manage. 2001;21(2):95-102.

22.

Ahmedzai SH Cough in cancer patients. Pulm Pharmacol Ther. 2004;17(6):415-423.

23.

Segura A. , Pardo J. , Jara C. , et al. An epidemiological evaluation of the prevalence of malnutrition in Spanish patients with locally advanced or metastatic cancer. Clin Nutr. 2005;24(5):801-814.

24.

Mercadante S. , Girelli D. , Casuccio A. Sleep disorders in advanced cancer patients: prevalence and factors associated. Support Care Cancer. 2004;12(5):355-359.

25.

Schiepers OJ , Wichers MC , Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29(2):201-217.

26.

Dunn AJ , Swiergiel AH , de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies ? Neurosci Biobehav Rev. 2005;29(4-5):891-909.

27.

Opp MR Cytokines and sleep. Sleep Med Rev. 2005;9(5): 355-364.

28.

Flacker JM , Lipsitz LA Neural mechanisms of delirium: current hypotheses and evolving concepts. J Gerontol A Biol Sci Med Sci. 1999;54(6):B239-B246.

29.

Hiramanek N. Itch: a symptom of occult disease. Aust Fam Physician. 2004;33(7):495-499.

30.

Jensen MP , Karoly P. , Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986;27(1): 117-126.